These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 24714704)
21. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726 [TBL] [Abstract][Full Text] [Related]
22. Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. Drenth JP; Tahvanainen E; te Morsche RH; Tahvanainen P; Kääriäinen H; Höckerstedt K; van de Kamp JM; Breuning MH; Jansen JB Hepatology; 2004 Apr; 39(4):924-31. PubMed ID: 15057895 [TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]
24. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925 [TBL] [Abstract][Full Text] [Related]
25. Surgical management and longterm follow-up of non-parasitic hepatic cysts. Gall TM; Oniscu GC; Madhavan K; Parks RW; Garden OJ HPB (Oxford); 2009 May; 11(3):235-41. PubMed ID: 19590653 [TBL] [Abstract][Full Text] [Related]
34. [Jaundice secondary to bile duct obstruction by polycystic liver disease]. Ramírez-Guillén F; Rosas-Carrasco O; Cajuste-Sequeira F; Barriga-Pérez Gil B; Cabanillas-Morel A; Rosales-Salinas AE; Peña-Pérez JA Gac Med Mex; 2016; 152(5):715-718. PubMed ID: 27792710 [TBL] [Abstract][Full Text] [Related]
35. Center is an important indicator for choice of invasive therapy in polycystic liver disease. D'Agnolo HM; Kievit W; van Munster KN; van der Laan JJ; Nevens F; Drenth JP Transpl Int; 2017 Jan; 30(1):76-82. PubMed ID: 27732751 [TBL] [Abstract][Full Text] [Related]
36. Polycystic Liver With Cardiac Compression Leading to Atrial Fibrillation: Case Report and Review of the Literature. Elfiky A; El Imad CT; Karam B; Mulrooney SM Cureus; 2020 May; 12(5):e7976. PubMed ID: 32523833 [TBL] [Abstract][Full Text] [Related]
37. Recurrent renal cell carcinoma leading to a misdiagnosis of polycystic liver disease: A case report. Liang C; Takahashi K; Kurata M; Sakashita S; Oda T; Ohkohchi N World J Gastroenterol; 2019 May; 25(18):2264-2270. PubMed ID: 31143076 [TBL] [Abstract][Full Text] [Related]
38. Advances in management of polycystic liver disease. Everson GT; Helmke SM; Doctor B Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):563-76. PubMed ID: 19072404 [TBL] [Abstract][Full Text] [Related]
39. Polycystic liver disease with obstructive jaundice: treatment with ultrasound-guided cyst aspiration. Lerner ME; Roshkow JE; Smithline A; Ng C Gastrointest Radiol; 1992; 17(1):46-8. PubMed ID: 1544558 [TBL] [Abstract][Full Text] [Related]
40. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]